Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ZEN003694 in Combination with Talazoparib in Triple-Negative Breast Cancer
2018-003906-26Phase 2Completed
- Sponsor
- Zenith Epigenetics
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ZEN3694 and talazoparib in triple-negative breast cancer (TNBC), sponsored by Zenith Epigenetics. Primary endpoint: Primary endpoints (Part 1). Started Jun 2019; status: completed.
02
Drugs
ZEN3694talazoparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2018-003906-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003906-26.